TABLE 1.
Summary of trials planned or ongoing using hPSC derived dopamine cell replacements for PD.
| Academic led trials | |||
|---|---|---|---|
| Country of work | Type of cell | Current status of trial | |
| Stem‐PD | Sweden/UK | ESC | Started 2023, 6 patients grafted to date (n = 8 in trial) |
| CiRA trial | Japan | Allogeneic iPSC | Started 2018, last patient last visit Dec 2023, n = 7 |
| Academic led/compassionate single case study | |||
| Kwang Soo Kim/MGH team | USA | Autologous iPSC |
N = 1, published. |
| Company trials | |||
| Company | Country of work | Type of cell | Current status of trial |
| Aspen Neuroscience | USA | Autologous iPSC | First patient grafted in 2024 |
| Bluerock Therapeutics/Bayer | USA | ESC | First trial of 12 patients completed in 2022 |
| Novo Nordisk | Global | ESC | In set up |
| Oryon Cell Therapies | USA | Autologous iPSC | Filing for Phase I trial |
| Ryne Bio | USA | iPSC | In set up |
| S. Biomedics | South Korea | ESC | First trial of 12 patients completed in Feb 2024 |
| Sumitomo | Japan now moving to the USA | iPSC | In set up in the USA |